Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University T&uuml;bingen, T&uuml;bingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Gallwitz B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/cd1f495ee6a240d9bfe076e1ace56906
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd1f495ee6a240d9bfe076e1ace56906
record_format	dspace
spelling	oai:doaj.org-article:cd1f495ee6a240d9bfe076e1ace569062021-12-02T06:28:30ZEmerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes1178-7007https://doaj.org/article/cd1f495ee6a240d9bfe076e1ace569062013-01-01T00:00:00Zhttp://www.dovepress.com/emerging-dpp-4-inhibitors-focus-on-linagliptin-for-type-2-diabetes-a11857https://doaj.org/toc/1178-7007Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University T&uuml;bingen, T&uuml;bingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP concentrations. Via this mechanism, insulin secretion is glucose-dependently stimulated and glucagon secretion inhibited. This results in a low risk for hypoglycemia. Furthermore, DPP-4 inhibitors are weight-neutral. Linagliptin is a novel DPP-4 inhibitor that, in contrast to the other members of this drug class, is eliminated by a biliary/hepatic route rather than by renal elimination. This property allows the use of linagliptin in type 2 diabetic patients with normal kidney function as well as in patients with renal insufficiency without dose adjustments. In comparative clinical studies, linagliptin was noninferior to other established antidiabetic agents, especially to metformin and sulfonylurea. It showed a superior safety profile over glimepiride regarding hypoglycemia, weight gain, a composite cardiovascular endpoint, and stroke. This review gives an overview on the efficacy and safety of linagliptin in comparison to the classical oral antidiabetic drugs as well as to the other DPP-4 inhibitors.Keywords: type 2 diabetes, oral antidiabetic drugs, incretin-based therapies, DPP-4 inhibitors, linagliptinGallwitz BDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 1-9 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Gallwitz B Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
description	Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University T&uuml;bingen, T&uuml;bingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP concentrations. Via this mechanism, insulin secretion is glucose-dependently stimulated and glucagon secretion inhibited. This results in a low risk for hypoglycemia. Furthermore, DPP-4 inhibitors are weight-neutral. Linagliptin is a novel DPP-4 inhibitor that, in contrast to the other members of this drug class, is eliminated by a biliary/hepatic route rather than by renal elimination. This property allows the use of linagliptin in type 2 diabetic patients with normal kidney function as well as in patients with renal insufficiency without dose adjustments. In comparative clinical studies, linagliptin was noninferior to other established antidiabetic agents, especially to metformin and sulfonylurea. It showed a superior safety profile over glimepiride regarding hypoglycemia, weight gain, a composite cardiovascular endpoint, and stroke. This review gives an overview on the efficacy and safety of linagliptin in comparison to the classical oral antidiabetic drugs as well as to the other DPP-4 inhibitors.Keywords: type 2 diabetes, oral antidiabetic drugs, incretin-based therapies, DPP-4 inhibitors, linagliptin
format	article
author	Gallwitz B
author_facet	Gallwitz B
author_sort	Gallwitz B
title	Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
title_short	Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
title_full	Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
title_fullStr	Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
title_full_unstemmed	Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
title_sort	emerging dpp-4 inhibitors: focus on linagliptin for type 2 diabetes
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/cd1f495ee6a240d9bfe076e1ace56906
work_keys_str_mv	AT gallwitzb emergingdpp4inhibitorsfocusonlinagliptinfortype2diabetes
_version_	1718399901425991680

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

Ejemplares similares